Cetuximab-Modified Human Serum Albumin Nanoparticles Co-Loaded with Doxorubicin and MDR1 siRNA for the Treatment of Drug-Resistant Breast Tumors

References

• Blair S, Garcia M, Davis T, et al. Hexachromatic bioinspired camera for image-guided cancer surgery. Sci Transl Med. 2021;13(592). doi:10.1126/scitranslmed.aaw7067
   Google Scholar
• Terrisse S, Derosa L, Iebba V, et al. Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment. Cell Death Differ. 2021;28(9):2778–2796. doi:10.1038/s41418-021-00784-1
   PubMed Web of Science ®Google Scholar
• Tian F, Zhang S, Liu C, et al. Protein analysis of extracellular vesicles to monitor and predict therapeutic response in metastatic breast cancer. Nat Commun. 2021;12(1):2536. doi:10.1038/s41467-021-22913-7
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang N, Li Q, Zhou Y, Luan Y. A two-pronged photodynamic nanodrug to prevent metastasis of basal-like breast cancer. Chem Commun (Camb). 2021;57(18):2305–2308. doi:10.1039/d0cc08162k
   PubMed Web of Science ®Google Scholar
• Zheng X, Zhao Y, Jia Y, et al. Biomimetic co-assembled nanodrug of doxorubicin and berberine suppresses chemotherapy-exacerbated breast cancer metastasis. Biomaterials. 2021;271:120716. doi:10.1016/j.biomaterials.2021.120716
   PubMed Web of Science ®Google Scholar
• Wan MM, Chen H, Da wang Z, et al. Nitric oxide-driven nanomotor for deep tissue penetration and multidrug resistance reversal in cancer therapy. Adv Sci (Weinh). 2021;8(3):2002525. doi:10.1002/advs.202002525
   PubMedGoogle Scholar
• Au KM, Balhorn R, Balhorn MC, Park SI, Wang AZ. High-performance concurrent chemo-immuno-radiotherapy for the treatment of hematologic cancer through selective high-affinity ligand antibody mimic-functionalized doxorubicin-encapsulated nanoparticles. Acs Central Sci. 2019;5(1):122–144. doi:10.1021/acscentsci.8b00746
   PubMed Web of Science ®Google Scholar
• Liu J, Ye Z, Xiang M, et al. Functional extracellular vesicles engineered with lipid-grafted hyaluronic acid effectively reverse cancer drug resistance. Biomaterials. 2019;223:119475. doi:10.1016/j.biomaterials.2019.119475
   PubMed Web of Science ®Google Scholar
• Liu J, Zhu C, Xu L, et al. Nanoenabled intracellular calcium bursting for safe and efficient reversal of drug resistance in tumor cells. Nano Lett. 2020;20:8102–8111. doi:10.1021/acs.nanolett.0c03042
   PubMed Web of Science ®Google Scholar
• He Y, Li X, Ma J, et al. Programmable codelivery of doxorubicin and apatinib using an implantable hierarchical-structured fiber device for overcoming cancer multidrug resistance. Small. 2019;15(8):1804397. doi:10.1002/smll.201804397
   Google Scholar
• Das T, Anand U, Pandey SK, et al. Therapeutic strategies to overcome taxane resistance in cancer. Drug Resist Updat. 2021;55:100754. doi:10.1016/j.drup.2021.100754
   PubMed Web of Science ®Google Scholar
• Dallavalle S, Dobričić V, Lazzarato L, et al. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors. Drug Resist Update. 2020;50:100682. doi:10.1016/j.drup.2020.100682
   PubMed Web of Science ®Google Scholar
• Zhang L, Li Y, Wang Q, et al. The PI3K subunits, P110alpha and P110beta are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer. Mol Cancer. 2020;19(1):10. doi:10.1186/s12943-019-1112-1
   PubMedGoogle Scholar
• Wang S, Liu X, Chen S, et al. Regulation of Ca(2+) signaling for drug-resistant breast cancer therapy with mesoporous silica nanocapsule encapsulated doxorubicin/siRNA cocktail. ACS Nano. 2019;13(1):274–283. doi:10.1021/acsnano.8b05639
   PubMedGoogle Scholar
• Haggag Y, Abu Ras B, El-Tanani Y, et al. Co-delivery of a RanGTP inhibitory peptide and doxorubicin using dual-loaded liposomal carriers to combat chemotherapeutic resistance in breast cancer cells. Expert Opin Drug Del. 2020;17(11):1655–1669. doi:10.1080/17425247.2020.1813714
   PubMed Web of Science ®Google Scholar
• Gu J, Fang X, Hao J, Sha X. Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery. Biomaterials. 2015;45:99–114. doi:10.1016/j.biomaterials.2014.12.030
   PubMed Web of Science ®Google Scholar
• Tsouris V, Joo MK, Kim SH, Kwon IC, Won YY. Nano carriers that enable co-delivery of chemotherapy and RNAi agents for treatment of drug-resistant cancers. Biotechnol Adv. 2014;32(5):1037–1050. doi:10.1016/j.biotechadv.2014.05.006
   PubMed Web of Science ®Google Scholar
• Dutta K, Bochicchio D, Ribbe AE, et al. Symbiotic self-assembly strategy toward lipid-encased cross-linked polymer nanoparticles for efficient gene silencing. ACS Appl Mater Interfaces. 2019;11(28):24971–24983. doi:10.1021/acsami.9b04731
   PubMedGoogle Scholar
• Wang H, Li F, Du C, et al. Doxorubicin and lapatinib combination nanomedicine for treating resistant breast cancer. Mol Pharm. 2014;11(8):2600–2611. doi:10.1021/mp400687w
   PubMed Web of Science ®Google Scholar
• Wang D, Xu X, Zhang K, et al. Codelivery of doxorubicin and MDR1-siRNA by mesoporous silica nanoparticles-polymerpolyethylenimine to improve oral squamous carcinoma treatment. Int J Nanomedicine. 2018;13:187–198. doi:10.2147/IJN.S150610
   PubMed Web of Science ®Google Scholar
• Wu Y, Zhang Y, Zhang W, et al. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles. Colloids Surf B Biointerfaces. 2016;138:60–69. doi:10.1016/j.colsurfb.2015.11.041
   PubMed Web of Science ®Google Scholar
• Wang C, Guan W, Peng J, et al. Gene/paclitaxel co-delivering nanocarriers prepared by framework-induced self-assembly for the inhibition of highly drug-resistant tumors. Acta Biomater. 2020;103:247–258. doi:10.1016/j.actbio.2019.12.015
   PubMed Web of Science ®Google Scholar
• Forbes DC, Peppas NA. Polycationic nanoparticles for siRNA delivery: comparing ARGET ATRP and UV-initiated formulations. ACS Nano. 2014;8(3):2908–2917. doi:10.1021/nn500101c
   PubMedGoogle Scholar
• Akinc A, Maier MA, Manoharan M, et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat Nanotechnol. 2019;14(12):1084–1087. doi:10.1038/s41565-019-0591-y
   PubMed Web of Science ®Google Scholar
• Prabha S, Vyas R, Gupta N, et al. RNA interference technology with emphasis on delivery vehicles-prospects and limitations. Artif Cells Nanomed Biotechnol. 2016;44(6):1391–1399. doi:10.3109/21691401.2015.1058808
   PubMed Web of Science ®Google Scholar
• Zhang J, Li X, Huang L. Non-viral nanocarriers for siRNA delivery in breast cancer. J Control Release. 2014;190:440–450. doi:10.1016/j.jconrel.2014.05.037
   PubMed Web of Science ®Google Scholar
• Lukashev AN, Zamyatnin AA Jr. Viral vectors for gene therapy: current state and clinical perspectives. Biochemistry (Mosc). 2016;81(7):700–708. doi:10.1134/S0006297916070063
   PubMedGoogle Scholar
• Wang Y, Luo Y-L, Chen Y-F, et al. Dually regulating the proliferation and the immune microenvironment of melanoma via nanoparticle-delivered siRNA targeting onco-immunologic CD155. Biomater Sci. 2020;8(23):6683–6694. doi:10.1039/d0bm01420f
   PubMedGoogle Scholar
• Haggag YA, Ibrahim RR, Hafiz AA. Design, formulation and in vivo evaluation of novel honokiol-loaded PEGylated PLGA nanocapsules for treatment of breast cancer. Int J Nanomedicine. 2020;15:1625–1642. doi:10.2147/IJN.S241428
   PubMed Web of Science ®Google Scholar
• Haggag YA, Yasser M, Tambuwala MM, et al. Repurposing of Guanabenz acetate by encapsulation into long-circulating nanopolymersomes for treatment of triple-negative breast cancer. Int J Pharmaceut. 2021;600:120532. doi:10.1016/j.ijpharm.2021.120532
   PubMed Web of Science ®Google Scholar
• Haggag Y, Elshikh M, El-Tanani M, et al. Nanoencapsulation of sophorolipids in PEGylated poly(lactide-co-glycolide) as a novel approach to target colon carcinoma in the murine model. Drug Deliv Transl Re. 2020;10(5):1353–1366. doi:10.1007/s13346-020-00750-3
   PubMed Web of Science ®Google Scholar
• Kamerkar S, LeBleu VS, Sugimoto H, et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature. 2017;546(7659):498–503. doi:10.1038/nature22341
   PubMed Web of Science ®Google Scholar
• Wang MY, Zhang L, Cai Y, et al. Bioengineered human serum albumin fusion protein as target/enzyme/pH three-stage propulsive drug vehicle for tumor therapy. Acs Nano. 2020;14(12):17405–17418. doi:10.1021/acsnano.0c07610
   PubMedGoogle Scholar
• Lee KJ, Ko EJ, Park Y-Y, et al. A novel nanoparticle-based theranostic agent targeting LRP-1 enhances the efficacy of neoadjuvant radiotherapy in colorectal cancer. Biomaterials. 2020;255:120151. doi:10.1016/j.biomaterials.2020.120151
   PubMed Web of Science ®Google Scholar
• Elzoghby AO, Samy WM, Elgindy NA. Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release. 2012;157:168–182. doi:10.1016/j.jconrel.2011.07.031
   PubMed Web of Science ®Google Scholar
• Fang H, Gai Y, Wang S, et al. Biomimetic oxygen delivery nanoparticles for enhancing photodynamic therapy in triple-negative breast cancer. J Nanobiotechnology. 2021;19(1):81. doi:10.1186/s12951-021-00827-2
   PubMed Web of Science ®Google Scholar
• Chilom CG, Bălan A, Sandu N, et al. Exploring the conformation and thermal stability of human serum albumin corona of ferrihydrite nanoparticles. Int J Mol Sci. 2020;21(24):9734. doi:10.3390/ijms21249734
   PubMed Web of Science ®Google Scholar
• Zhou Y, Ren X, Hou Z, et al. Engineering a photosensitizer nanoplatform for amplified photodynamic immunotherapy via tumor microenvironment modulation. Nanoscale Horiz. 2021;6(2):120–131. doi:10.1039/d0nh00480d
   PubMedGoogle Scholar
• Sleep D. Albumin and its application in drug delivery. Expert Opin Drug Del. 2015;12(5):793–812. doi:10.1517/17425247.2015.993313
   PubMed Web of Science ®Google Scholar
• Low K, Wacker M, Wagner S, Langer K, von Briesen H. Targeted human serum albumin nanoparticles for specific uptake in EGFR-expressing colon carcinoma cells. Nanomedicine. 2011;7(4):454–463. doi:10.1016/j.nano.2010.12.003
   PubMedGoogle Scholar
• Zhang X, Li Y, Wei M, et al. Cetuximab-modified silica nanoparticle loaded with ICG for tumor-targeted combinational therapy of breast cancer. Drug Deliv. 2019;26(1):129–136. doi:10.1080/10717544.2018.1564403
   PubMed Web of Science ®Google Scholar
• Hofmann M, McCormack E, Mujic M, et al. Increased plasma colloid osmotic pressure facilitates the uptake of therapeutic macromolecules in a xenograft tumor model. Neoplasia. 2009;11:812–822. doi:10.1593/neo.09662
   PubMed Web of Science ®Google Scholar
• Gudino V, Pohl SÖ-G, Billard CV, et al. RAC1B modulates intestinal tumourigenesis via modulation of WNT and EGFR signalling pathways. Nat Commun. 2021;12:2335. doi:10.1038/s41467-021-22531-3
   PubMedGoogle Scholar
• Lu ZY, Truex NL, Melo MB, et al. IgG-engineered protective antigen for cytosolic delivery of proteins into cancer cells. Acs Central Sci. 2021;7:365–378. doi:10.1021/acscentsci.0c01670
   PubMedGoogle Scholar
• Sharifpour E, Ghaedi M, Asfaram A, et al. Modeling and optimization of ultrasound-assisted high performance adsorption of basic Fuchsin by starch-capped zinc selenide nanoparticles/AC as a novel composite using response surface methodology. Int J Biol Macromol. 2020;152:913–921. doi:10.1016/j.ijbiomac.2020.02.236
   PubMed Web of Science ®Google Scholar
• Foster DJ, Brown CR, Shaikh S, et al. Advanced siRNA designs further improve in vivo performance of GalNAc-siRNA conjugates. Mol Ther. 2018;26(3):708–717. doi:10.1016/j.ymthe.2017.12.021
   PubMed Web of Science ®Google Scholar
• Han NN, Li X, Tao L, Zhou Q. Doxorubicin and rhein loaded nanomicelles attenuates multidrug resistance in human ovarian cancer. Biochem Biophys Res Commun. 2018;498(1):178–185. doi:10.1016/j.bbrc.2018.01.042
   PubMed Web of Science ®Google Scholar
• Yu J, Zhou P, Asenso J, et al. Advances in plant-based inhibitors of P-glycoprotein. J Enzyme Inhib Med Chem. 2016;31:867–881. doi:10.3109/14756366.2016.1149476
   PubMed Web of Science ®Google Scholar
• Lusvarghi S, Ambudkar SV. ATP-dependent thermostabilization of human P-glycoprotein (ABCB1) is blocked by modulators. Biochem J. 2019;476(24):3737–3750. doi:10.1042/Bcj20190736
   PubMedGoogle Scholar
• Zhang YJ, Sun T, Jiang C. Biomacromolecules as carriers in drug delivery and tissue engineering. Acta Pharmaceutica Sinica B. 2018;8(1):34–50. doi:10.1016/j.apsb.2017.11.005
   PubMed Web of Science ®Google Scholar
• Ryu JH, Shin J-Y, Kim SA, et al. Non-invasive optical imaging of matrix metalloproteinase activity with albumin-based fluorogenic nanoprobes during angiogenesis in a mouse hindlimb ischemia model. Biomaterials. 2013;34(28):6871–6881. doi:10.1016/j.biomaterials.2013.05.074
   PubMedGoogle Scholar